Why Has ADHD Diagnosis Become So Contentious in the UK?

Originally published December 2025 · Updated May 2026 with the March 2026 British Journal of Psychiatry over-diagnosis paper by Professor Samuele Cortese, the November 2025 NHS England ADHD Taskforce final report, the March 2026 independent government review interim report, and the December 2025 House of Commons Library ADHD statistics

Few areas of health generate as much simultaneous public concern, clinical debate, and personal controversy as ADHD diagnosis in the UK. Depending on who you read, ADHD is either catastrophically under-diagnosed — with millions of people suffering without support — or it has become a fashionable label applied too readily to traits that are part of normal human variation.

Both framings exist in public discourse. The research, as of 2026, tells a more precise and more useful story.

A team of experts led by Professor Samuele Cortese from the University of Southampton has concluded that there is no robust evidence that ADHD is over-diagnosed in the UK. At the same time, up to 2,759,626 people may have been waiting for an ADHD assessment at the end of December 2025 — a figure that places the UK's ADHD service capacity in a state of acute crisis.

Understanding both findings — and why they are not contradictory — is the most useful starting point for anyone trying to make sense of the controversy.

TL;DR

• Experts led by Professor Samuele Cortese at the University of Southampton have found no robust evidence that ADHD is over-diagnosed in the UK, warning instead that people with ADHD are waiting too long for assessment, support, and treatment.
• Up to 2,759,626 people may have been waiting for an ADHD assessment at the end of December 2025. Around 61.6% of adults and 65.8% of children had been on a waiting list for over a year.
• Average waiting time for an initial adult ADHD assessment via the standard NHS pathway is over two years across the UK. In some regions including parts of Kent, Sussex, and London, waits are between five and seven years.
• The March 2026 independent government review found that relatively stable underlying prevalence can coexist with rapidly rising diagnosis, referral, and service demand — the evidence points to a complex picture, not simple over-diagnosis.

Primary care data show a sharp acceleration in diagnoses after 2020, with incidence among women aged 20 to 24 more than doubling compared with pre-pandemic trends, while increases among males have been smaller.

The November 2025 NHS England ADHD Taskforce final report found that cross-sector services are under significant pressure due to the growing number of people seeking assessment and support.

The Right to Choose pathway provides a legal route to NHS-funded ADHD assessment through approved private providers — bypassing local NHS waiting lists.

The Scale of the Problem

The numbers are striking enough to require clear statement before the debate around them is examined.

NHS Digital has estimated that around 2.5 million people in England have ADHD as of February 2026. This includes those without a formal diagnosis and is based on prevalence data from NICE, who suggest that around 3 to 4% of adults and 5% of children and young people have ADHD.

Up to 2,759,626 people may have been waiting for an ADHD assessment at the end of December 2025. Around 10.2% of adults and 9% of children had been on the waiting list for less than 13 weeks. Around 61.6% of adults and 65.8% of children had been on a waiting list for over a year.

The average waiting time for an initial adult ADHD assessment via the standard NHS pathway is over two years across the UK. While some areas might quote 18 to 24 months, it is not uncommon for patients in regions like Kent, Sussex, and parts of London to be told the wait is between five and seven years.

These are not waiting list statistics in an abstract sense. They represent millions of people — many of them children — living without diagnosis, without treatment, and without the accommodations and support that a diagnosis enables, for years at a time. The educational, employment, mental health, and social consequences of this diagnostic delay accumulate across that period.

With waiting lists for assessment increasing across the UK, the ADHD Taskforce compellingly argues that the prevailing issue is, in fact, significant unmet need and underdiagnosis, resulting in serious educational, employment, social, physical, and other harms.

Is ADHD Being Over-Diagnosed?

The over-diagnosis argument has been a recurring feature of public debate about ADHD for two decades. It reached particular intensity in the UK around 2024 and 2025, driven partly by the visible surge in adult diagnoses, partly by high-profile media coverage, and partly by the rapid growth of private diagnostic services.

The March 2026 response from the research community is the most authoritative rebuttal of the over-diagnosis claim yet published.

Experts are warning that far from being over-diagnosed, people with ADHD are waiting too long for assessment, support and treatment. The paper, published in the British Journal of Psychiatry in March 2026, is titled "ADHD (over) diagnosis: fiction, fashion, and failure."

Professor Samuele Cortese and his team at the University of Southampton found no robust evidence that ADHD is over-diagnosed in the UK.

The March 2026 independent government review reached a similarly nuanced conclusion: the evidence points to a complex picture in which relatively stable underlying prevalence can coexist with rapidly rising diagnosis, referral, and service demand. This does not imply that one set of trends is real and the other is not.

This is an important distinction. The rise in ADHD diagnoses does not necessarily mean prevalence has increased — it may primarily reflect improved recognition of a condition that was systematically under-identified for decades, particularly in adults, women, and people without hyperactivity. Primary care data show a sharp acceleration in diagnoses after 2020, with incidence among women aged 20 to 24 more than doubling compared with pre-pandemic trends, while increases among males have been smaller.

The surge in adult female diagnoses is consistent with what is known about historical under-identification. ADHD diagnostic criteria and assessment tools were developed primarily from research in male children. Adult presentations — particularly inattentive-predominant ADHD, which is more common in women — were not well represented in the evidence base that shaped clinical practice for decades. The diagnostic surge among adult women is most plausibly understood as correction of historical under-identification rather than evidence of over-diagnosis.

The Independent Government Review

The independent ADHD Taskforce established to tackle challenges in ADHD care published its final report on 6 November 2025. The report assessed services across health, education, employment, and the criminal justice system and recognised that cross-sector services are under significant pressure due to the growing number of people seeking assessment and support, resulting in long waits for diagnosis and treatment.

The March 2026 independent government review — examining mental health conditions, ADHD, and autism — provided the most comprehensive official synthesis of the evidence to date. Its findings are worth understanding in detail.

The population data suggest that epidemiological estimates of ADHD appear broadly stable, even though diagnoses and referrals are rising steeply. The review found a more complex picture in which stable underlying prevalence can coexist with rapidly rising diagnosis — with the evidence pointing to changing patterns of recognition rather than changing rates of the condition itself.

The next phase of the review will examine more closely the quality and consistency of assessments, variation in diagnostic practice, and the extent to which diagnosis is followed by evidence-based treatment. Among children and young people, the proportion of diagnoses followed by medication prescribing has roughly halved.

This last finding is significant. If diagnoses are rising rapidly but the proportion followed by medication treatment is falling — suggesting either that the newly diagnosed population has lower severity presentations, or that treatment capacity has not kept pace with diagnostic capacity — this has direct implications for whether the diagnostic rise represents clinical harm or benefit.

What Is Driving the Surge

Several factors have contributed to the rapid increase in ADHD referrals and diagnoses over the past five years.

Increased public awareness — ADHD has become considerably more visible in public discourse, particularly on social media platforms where neurodivergent communities have shared experiences and information at scale. This has led many people to recognise ADHD traits they had previously attributed to personality differences, laziness, or anxiety — and to seek assessment.

COVID-19 effects — the pandemic-related disruption to routine, structure, and in-person learning removed the external scaffolding that many people with undiagnosed ADHD had been using to compensate. The absence of this structure made ADHD traits significantly more impairing and more visible, driving a surge in referrals from 2020 onward. Primary care data show a sharp acceleration in diagnoses after 2020.

Historical under-identification — as described above, systematic under-diagnosis of ADHD in adults and in women over decades has created a diagnostic backlog now becoming visible as awareness improves and services expand.

Growth of private diagnostic services — underfunding of NHS adult ADHD services has resulted in a significant growth of independent providers, whose numbers have increased in response to the unmet demand. The availability of private diagnosis — at cost — has enabled people who can afford it to bypass NHS waiting times, increasing the total diagnostic output.

The Quality and Consistency Question

While the over-diagnosis argument is not well supported by the evidence, there is a legitimate adjacent question about the quality and consistency of ADHD assessment.

The independent government review will examine more closely the quality and consistency of assessments and variation in diagnostic practice. This is a different question from whether ADHD is being over-diagnosed — it is a question about whether assessments are being conducted to the same standard across different providers.

ADHD assessment is complex and time-intensive. A thorough ADHD assessment is not a quick chat — it involves detailed psychiatric interviews, gathering historical evidence, and ruling out other conditions, all of which are time-intensive for clinicians. Variation in the rigour with which this process is conducted across NHS trusts and private providers is a legitimate concern — particularly as the volume of assessments has increased rapidly without proportional increases in specialist capacity.

This concern is distinct from over-diagnosis and should not be conflated with it. An assessment that is conducted inconsistently or with insufficient rigour could produce both false positives and false negatives — the concern about quality cuts in both directions.

Accessing Assessment in 2026

For people in England who suspect they have ADHD and are trying to access assessment, the practical landscape in 2026 is as follows.

NHS standard pathway — referral from GP to specialist ADHD service. Average waiting time over two years, with some regions quoting five to seven years. This is the most common experience.

Right to Choose — Right to Choose allows NHS patients in England to be referred for assessment to a qualified private provider that has an NHS contract. The NHS funds the entire process at no cost to the patient. In 2026, standard Right to Choose waiting lists for an initial assessment typically span nine to fifteen months — considerably shorter than the NHS standard pathway but still lengthy. The most well-known providers accepting Right to Choose referrals include Psychiatry-UK and ADHD 360.

Private assessment — available without referral from a range of private psychiatrists and specialist services. Costs vary but full assessments typically range from £600 to £1,500. Private diagnosis is legally valid for workplace accommodations and educational support. In 2025, 95% of UK universities reported accepting Right to Choose and private diagnostic reports as valid evidence for Disabled Students' Allowances applications.

Scotland, Wales, and Northern Ireland — the Right to Choose pathway applies only in England. Access routes in devolved nations vary — waiting times in Scotland and Wales are similarly long.

Frequently Asked Questions

Is ADHD over-diagnosed in the UK?

The research consensus is no. A March 2026 paper in the British Journal of Psychiatry by Professor Samuele Cortese and colleagues at the University of Southampton found no robust evidence that ADHD is over-diagnosed in the UK, warning instead that people with ADHD are waiting too long for assessment, support, and treatment. The March 2026 independent government review similarly found that stable underlying prevalence can coexist with rising diagnosis rates — pointing to improved recognition rather than over-diagnosis.

How long is the ADHD waiting list in the UK?

Up to 2,759,626 people may have been waiting for an ADHD assessment at the end of December 2025, with around 61.6% of adults and 65.8% of children having been on a waiting list for over a year. Average waiting time for adult assessment via the standard NHS pathway is over two years, with some regions quoting five to seven years.

What is Right to Choose for ADHD?

Right to Choose is a legal right allowing NHS patients in England to be referred for ADHD assessment to a qualified private provider with an NHS contract, at no cost to the patient. It bypasses local NHS waiting lists and typically offers faster access than the standard pathway. Ask your GP for a Right to Choose referral — they are legally required to offer it.

Why have ADHD diagnoses increased so much?

The independent government review found the evidence points to a complex picture in which stable underlying prevalence coexists with rising diagnosis and service demand — reflecting changing patterns of recognition rather than changing rates of the condition. Key drivers include increased public awareness, the COVID-19 disruption to compensatory routines, historical under-identification of ADHD in adults and women, and the growth of private diagnostic services.

Why are women being diagnosed with ADHD more than before?

Primary care data show incidence among women aged 20 to 24 more than doubling compared with pre-pandemic trends. This is most plausibly explained by historical under-identification — ADHD diagnostic criteria and tools were developed primarily from research in male children, systematically missing the inattentive presentations more common in women. The surge in female diagnoses represents correction of this historical bias rather than over-diagnosis.

Is a private ADHD diagnosis valid in the UK?

Yes — a diagnosis from a qualified clinician, whether NHS or private, is clinically valid. In 2025, 95% of UK universities reported accepting private diagnostic reports as valid evidence for Disabled Students' Allowances applications and internal support plans, and diagnoses are legally recognised for workplace adjustments under the Equality Act 2010.

The Bottom Line

The ADHD diagnosis controversy in the UK is best understood not as a debate between those who think ADHD is real and those who think it is over-diagnosed — but as a collision between rapidly expanding demand and comprehensively inadequate supply.

The research is clear: there is no robust evidence of over-diagnosis. The prevailing issue is significant unmet need and underdiagnosis, resulting in serious educational, employment, social, physical, and other harms. The millions of people on waiting lists are not the victims of a diagnostic fashion. They are people with a genuine neurodevelopmental condition trying to access assessment and treatment in a system that has not kept pace with the scale of need.

The November 2025 NHS England ADHD Taskforce final report recognised that services are under significant pressure and set clear expectations for integrated care boards to improve access, experience, and outcomes over the next three years. Whether those expectations translate into meaningful improvement in waiting times will determine the lived experience of the millions of people currently in the queue.

For structured support with the daily management challenges of ADHD — focus, stress, sleep, and the lifestyle foundations that complement medical treatment — the ADHD Reset, Stress Reset, and Sleep Reset from the Reset Series™ provide practical evidence-based frameworks. The Reset Companion provides daily structured support alongside professional assessment and treatment.

Related reading: AI, Anxiety and the Future of Calm · Cortisol Explained — and How to Reduce It Without Making Things Worse · Has Autism Become Over-Diagnosed? What the Evidence Shows

Popular Articles